pharma · Renal Impairment · Urinary Tract Infection · SPRO
Spero Therapeutics
Spero Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SPRO. Primary therapeutic focus areas include Renal Impairment, Urinary Tract Infection, complicated urinary tra
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
- Founded
- 2013
- Employees
- 45
- Programs
- 21
- Drugs
- 9
- Patents
- 16
Placebo
Phase 2 · small molecule · Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Placebo for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) is a Phase 2 program (small_molecule) at Spero Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SPR720-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Spero Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
- Status
- completed
- Trials
- 1